EdgeTestMarket TodayOptions TodayIPO
Start free

TARSONSTarsons Products Limited

Rs 298.3▼ -0.57%
Market closedEquity EOD 26 Oct
Compare
52-week rangeThe lowest and highest prices the stock traded at over the last year, from each day's intraday low and high. The marker is today's close: 0% means it sits at the year's low, 100% at the high. It describes where the price is, not where it is going.63.6% up the range
Rs 164Rs 375
TARSONS price
Daily candles, adjusted for splits and bonus issues so a corporate action does not show as a crash. Pick a window from one month to the full history, add indicators, or open it full screen.
EOD 26 Oct
IndicatorsVolume

Loading TARSONS price...

At a glance
Each figure is shown against the company's sector (the track: the dot is this company, the tick is the sector middle) and, where we hold the yearly filings, against its own recent years (the small trend line).
Market capWhat the whole company is worth on the stock market today: share price times the number of shares. It measures size, not quality.
Rs 1,587 cr
Larger than 67% of 6 peers
sector middle Rs 744 cr
P/EPrice to earnings: how many rupees investors pay for each rupee of profit the company made over the last twelve months. Compare it with similar companies rather than reading it alone.
142.7x
Highest of 5 peers
sector middle 30.5x
Price to bookPrice to book: the share price divided by the shareholders' money per share in the latest balance sheet. Around 1 means the market values the company close to its book value.
2.5x
Lower than 60% of 5 peers
sector middle 3.9x
ROEReturn on equity: the year's profit as a percentage of the shareholders' money in the business. It shows how much the company earns on what its owners have put in.
1.8%
Lowest of 5 peers
sector middle 9.9%
FY23 14.2%FY26 2.3%
ROCEReturn on capital employed: operating profit as a percentage of all the long-term money in the business, owners' and lenders'. It shows how well the company uses its capital, whatever the mix of debt.
4.8%
Lower than 80% of 5 peers
sector middle 11.6%
FY23 17.1%FY26 4.8%
Debt to equityBorrowings divided by shareholders' money. 0 means no borrowings; 1 means it owes as much as its owners have put in. Not shown for banks and lenders, whose borrowing is their business.
0.60
Highest of 5 peers
sector middle 0.10
FY23 0.19FY26 0.60
Dividend yieldDividends paid over the last year as a percentage of the company's market value: roughly what Rs 100 of shares paid out in cash.
0.0%
Lower than 40% of 5 peers
sector middle 0.0%
Sales growthHow much the latest quarter's sales grew against the same quarter a year earlier.
+20.7%
Higher than 60% of 5 peers
sector middle +18.0%
FY24 4.7%FY26 7.7%

Peers are the listed companies in the exchange's own industry group: Medical Equipment & Supplies. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

What the numbers say
Short lines written by fixed rules from the company's own filings and shareholding. A line appears only when the figures cross the rule (for example sales growing three years running), and each names the numbers behind it. Nothing here is a view on whether to own the share.

Latest quarterIn the quarter to June 2026 (results filed 10 Aug 2026), sales rose 20.7% from a year earlier to Rs 110 cr and profit turned to a loss of Rs 1.4 cr from Rs 1.8 cr a year earlier.

Going well
  • Sales grew 3 years running (Rs 283 cr in FY23 to Rs 422 cr in FY26).
  • Cash from operations was at least the reported profit in each of FY24, FY25, FY26.
Worth watching
  • Profit fell 3 years running (Rs 80.7 cr in FY23 to Rs 14.3 cr in FY26).
  • Operating margin fell from 45.8% in FY23 to 27.9% in FY26.
  • Profit before interest covered interest 2.0 times in FY26 (Rs 22 cr of interest).
  • Return on equity stayed under 10% from FY24 to FY26 (highest 7.0%).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

How the share moved on results
For each quarterly result we hold: the change from the share's close on the last trading day before the filing to its close on the first trading day after it. Results can land during market hours or after the close, and this window covers both. It shows what happened, not what will happen next time.

Over the last 18 results, the share rose on 4 and fell on 14, and moved by 3% or more on 14.

Q4 FY22Q4 FY23Q4 FY24Q4 FY25Q1 FY27

Q1 FY27: results filed 10 Aug 2026. The share went from its close on 7 Aug 2026 to its close on 11 Aug 2026 -4.84%.

Where every Rs 100 of sales goes
From the company's own yearly results. Each year is scaled to that year's sales, so you compare shares, not size: how much went on running costs, depreciation, interest and tax, and how much was left as profit.
4 financial years
Sales, last 12 months
Rs 441 Cr
Profit, last 12 months
Rs 11 Cr
Earnings per share
Rs 2.1
Profit growth (qtr, YoY)
-180.99%

Of every Rs 100 of sales in FY26, Rs 72 went on running costs, Rs 23 on depreciation, Rs 5.3 on interest and Rs 1.8 on tax; Rs 3.4 was left as profit.

FY23
54
10
9.9
28
FY24
66
14
14
FY25
72
16
7.6
FY26
72
23
Sales (Rs 100)Other incomeRunning costsDepreciationInterestTaxProfit

Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.

How fast it has grown
Compound growth per year in sales, profit and earnings per share between financial years, from the company's own results. A span appears only if our filings cover both ends of it.
Sales
3 yrs
+14.3%/yr
Latest qtr
+20.7%
Profit
3 yrs
-43.8%/yr
Latest qtr
-181.0%

Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.

Health check, year by year
Margins, returns, debt and interest cover for each financial year. Each row is coloured against this company's own usual level, so you see what is improving and what is slipping.
MeasureFY23FY24FY25FY26
Sales growthSales against the previous financial year.-4.7%32.4%7.7%
Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales.45.8%33.7%28.2%27.9%
Net marginProfit after everything, per Rs 100 of sales.28.5%14.4%7.6%3.4%
ROEProfit as a percentage of shareholders' money (from the March balance sheet).14.2%7.0%4.7%2.3%
ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'.17.1%9.3%7.1%4.8%
Debt to equityBorrowings divided by shareholders' money. Lower is safer.0.19x0.42x0.52x0.60x
Interest coverHow many times operating profit covers the interest bill. Higher is safer.25.2x7.0x3.3x2.0x

Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).

What it owns, and how that is paid for
Straight from the March balance sheet in the company's annual filing. Both bars are the whole balance sheet: what the company owns, and where the money for it came from.
as at 2026-03-31

At FY26 it owned Rs 1,186 Cr of assets. Its owners funded 54% of that and borrowings 32%.

What it owns
69%
11%
Plant, property and projects815 Cr
Goodwill and intangibles60 Cr
Inventory130 Cr
Owed by customers85 Cr
Cash and bank25 Cr
Everything else70 Cr
How that is paid for
54%
32%
12%
Shareholders635 Cr
Borrowings383 Cr
Owed to suppliers20 Cr
Other liabilities148 Cr
Cash and equivalents
Rs 23 Cr
Net debt
Rs 359 Cr
Current ratio
1.01x
short-term assets per rupee due soon
Book value / share
Rs 119
Return on assets
0.9%
EV / EBITDA
13.8x

From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.

Where the cash went
Profit is an accounting figure; cash flow is what actually moved. Cash from running the business, plus or minus what was spent on or received from investments, plus or minus what came from or went to lenders and shareholders, equals the change in cash.

In FY26 the business itself brought in Rs 118 Cr, spent Rs 126 Cr on plant and equipment, and cash fell by Rs 2 Cr over the year.

From running the business
+118 Cr
Spent on or received from investing
-130 Cr
From or to lenders and shareholders
+9 Cr
Net change in cash
-2 Cr
Cash from operations for every Rs 100 of profit
Rs 94
FY23
Rs 241
FY24
Rs 384
FY25
Rs 827
FY26

Rs 100 or more means every rupee of reported profit arrived as cash.

Full financial year to 2026-03-31, from the company's cash flow statement.

Against its sector
Where this stock sits within its own sector on each measure. The marker is its position in the peer group and the notch is the sector median. A position is a fact about the cohort, not a view on the stock.
Medical Equipment & Supplies · 16
P/E142.73vs 30.47 median
Cheapest: FABTECH 8.84Priciest: TARSONS 142.73
Net margin2.51%vs 10.77% median
Lowest: TARSONS 2.51%Highest: POLYMED 15.67%
Revenue growth20.66%vs 18.04% median
Lowest: FABTECH 10.26%Highest: FISCHER 249.42%
Compared against
APRAMEYAAVIENCEDENTALKARTFABTECHFISCHERGKBGMLLAXMIDENTLMADHAVBAUGMHHLMOLBIONURECAOSELDEVICEPOLYMEDQLINEQMSMEDI

Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.

Peers side by side
Every company in the same NSE industry group that we hold figures for, largest first. Tap any heading to sort by it. The same figures as the At a glance tiles, worked out the same way for every company.
Medical Equipment & Supplies · 7 shown
Company
POLYMED
Poly Medicure Limited
14,631 cr46.5x4.7x9.9%13.2%0.1115.7%+30.3%0.24%
FISCHER
Fischer Medical Ventures Limited
1,767 cr10.6x4.6x7.7%12.7%0.198.1%+249.4%0.02%
TARSONS
Tarsons Products Limited
1,587 cr142.7x2.5x1.8%4.8%0.602.5%+20.7%0.00%
LAXMIDENTL
Laxmi Dental Limited
945 cr30.5x3.9x12.7%11.5%0.0010.8%+13.9%0.00%
FABTECH
Fabtech Technologies Limited
543 cr8.8x1.3x11.6%11.6%0.1011.7%+10.3%0.00%
QMSMEDI
QMS Medical Allied Services Limited
334 cr--------
NURECA
Nureca Limited
296 cr72.1x1.6x2.4%3.4%0.002.8%+18.0%0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

The business
Sales and net profit from the company's own filings, by financial year or by quarter. Hover any bar for that period's complete figures including operating margin and the change against the comparable earlier period. The single TTM figure above is the sum of the last four quarters.
4 years · 19 quarters
Full financial years - the long arc of the business.
Sales growth
+14.3%
a year, 3 years
Profit growth
-43.8%
a year, 3 years
Operating margin
27.9%
latest year
Sales by financial yearRs 423 Cr
Net profit by financial yearRs 14 Cr
FY234 full years · hover a yearFY26

Operating margin has gone from 45.8% to 27.9% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.

Dividends paid
Cash paid per share, from the exchange's corporate-action record, restated to today's share count across bonuses and splits. Dates shown are ex-dates: you must own the shares before that date to receive the payment.
Rs 670 in 2024
Paid 1 of 1 yrs
what 2024's payouts come to on Rs 1 lakh at today's price · nothing declared in the last twelve months
What each year paid, on Rs 1 lakh
670
24

2024 paid Rs 2.00 per share, about Rs 670 on Rs 1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.

Large institutional deals
Bulk and block deals reported by the exchange, where a single large trade is disclosed along with the counterparty's name. Only deals above the exchange's disclosure threshold appear here.
last 8
DatePartySideQtyPriceValue
2026-08-14NK SECURITIES RESEARCH PRIVATE LIMITEDSELL3,74,087351.18Rs 13.14 Cr
2026-08-14NK SECURITIES RESEARCH PRIVATE LIMITEDBUY3,74,087350.87Rs 13.13 Cr
2026-08-14JUNOMONETA FINSOL PRIVATE LIMITEDSELL3,27,650351.12Rs 11.5 Cr
2026-08-14JUNOMONETA FINSOL PRIVATE LIMITEDBUY3,25,555350.74Rs 11.42 Cr
2026-08-14MICROCURVES TRADING PRIVATE LIMITEDBUY2,84,512356.75Rs 10.15 Cr
2026-08-14MICROCURVES TRADING PRIVATE LIMITEDSELL2,84,512357.03Rs 10.16 Cr
2026-07-21NK SECURITIES RESEARCH PRIVATE LIMITEDSELL3,50,036318.86Rs 11.16 Cr
2026-07-21NK SECURITIES RESEARCH PRIVATE LIMITEDBUY3,50,036318.63Rs 11.15 Cr
Technical snapshot
Momentum, trend and delivery-based conviction from the actual price and volume history.
EOD 26 Oct
RSI (14) - momentum
38.8Neutral
0 oversold3070overbought 100
Delivery % - genuine buying vs churn
52.6%Near average
today 52.6%20d avg 43.4%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50-DMA
-9.32%
vs 200-DMA
+17.54%
1-month
-11.07%
3-month
-4.62%
1-year
+2.70%
Realized vol (30d)
50.7%
Insider trading disclosures
Promoter, director and other insider trades in the company's own shares, as disclosed to the exchange under SEBI's insider-trading regulations - usually within a few days of the transaction.
last 18 months

Insider trading data unavailable.

Recent announcements
The company's own filings to the exchange - results, board meetings, investor calls - with a link to the source document.
last 6 months

Announcements unavailable.

Want to test a strategy on TARSONS?

Backtest an equity strategy on real market data, free - no card needed.

Start free

Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.